[15]. Feagan B G, Sandborn W J, D'Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, place...
NMPA按照优先审评审批程序加快批准了Tremfya上市。 原文出处:TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
IL-2 was first identified as a growth factor capable of driving the expansion of activated human T cell populations. In the more than 40 years since its discovery, a tremendous amount has been learned regarding the mechanisms that regulate the expression of both IL-2 and its cell surface rece...
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients The goal of this clinical research study is to learn if ustekinumab can help to control immune-related diarrhea and/or colitis in cancer patients. ...
Deunoxavir Marboxil Tablets (ADC189) is a cap-dependent nucleic acid endonuclease inhibitor. The Tablets inhibit the cap-dependent nucleic acid endonuclease in influenza viruses, preventing their transcriptin, and, consequently, rendering them incapable of replicating. This potent action enables Deunox...
KEGGWikiATCDrug Bank D02934安纳白介素 L04AC03 DB00026 研发状态 批准上市 10条最早获批的记录, 后查看更多信息 适应症国家/地区公司日期 新型冠状病毒感染 欧盟 Swedish Orphan Biovitrum AB 2002-03-08 新型冠状病毒感染 挪威 Swedish Orphan Biovitrum AB ...
calcineurin inhibitorBackground: Success with calcineurin inhibitors (CNIs) such as cyclosporine A (CSA) and tacrolimus (TAC) in organ transplantation has demonstrated that cytokine suppression is a key factor in patient management. However, the exact effects of recently introduced immunosuppressive agents...
货号12-7114-82 CNY3,772.00 有货 查看价格 批量或定制请求 Application Created with Sketch. 图:1/32 IL-1 beta (Pro-form) Antibody (12-7114-82) in Flow In vitro-cultured mouse monocytes unstimulated (left) or stimulated with LPS (right), in the presence of Protein Transport ...
(aldesleukin; trade name Proleukin) was the first immunotherapy approved by the U.S. Food and Drug Administration (FDA) in 1992 [58,59]. The activation of effector T cells as the main function of IL-2 was contested when ablation ofIl2,Il2raandIl2rbexpression in mice caused lethal lympho...
Ilginatinib (NS-018) is a highly active JAK2 inhibitor, with an IC50of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). Ilginatinib (NS-018) also inhibits Src-family kinases, especially SRC and FYN...